Many drugs like otezla's prescription data gets reported by a company called IMS.
Not all drugs do. Revlimid and pomalyst do not.
But otezla does. (others that get reported weekly are Gilead's sovaldi does as does Pharmacyclic's imbruvica)
Analysts who cover pharma/biotech stocks would be a group of companies who would be interested in this data. So they likely subscribe and send it to their clients periodically as part of the 'analyst' services they provide.
So, no, otezla prescription data is NOT only known by internal Celgene employees.
And once again, I firmly believe it is ramping nicely. Ahead of some analysts predictions.
And not believing it is fine... The company will report quarterly results in about 2 months.
So you'll know how its performing against company expectations then. I prefer to seek out the weekly data to get a more frequent read on how its ramping.
